denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Qasim, W.
1931 - Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial
2043 - Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy
2043 - Automated Lentiviral Transduction of T Cells with Cars Using the Clinimacs Prodigy
Qayed, M.
Qazilbash, M.
152 - Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
187 - Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
738 - Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial
854 - A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids
929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
1933 - Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?
1980 - Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
1992 - Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
3128 - Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease
3135 - Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation
3136 - Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit
3155 - Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
3186 - Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients
3192 - In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials
3194 - Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant
3225 - Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience
3746 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes
4376 - Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results
187 - Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
738 - Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial
854 - A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids
929 - Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
1933 - Histologic Confirmation for Patients Presenting with Gastrointestinal Graft Versus Host Disease: How to Interpret Histologic Grade 1 (Does It Matter)?
1980 - Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM
1992 - Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma
3128 - Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease
3135 - Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation
3136 - Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit
3155 - Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma
3186 - Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients
3192 - In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials
3194 - Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant
3225 - Outcomes of Haploidenitical Stem Cell Transplants for De Novo Acute Myeloid Leukemia, Myelodysplastic Syndrome and Acute Myeloid Leukemia Arising from MDS: The MD Anderson Experience
3746 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes
4376 - Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results
Qi, A.
Qi, J.
Qi, J.
QI, J.
Qi, W.
Qi, Y.
Qian, H.
Qian, M.
Qian, P.
1166 - Amino Acid Transporter X Is Required for Hematopoietic Stem Cell Maintenance through Regulating Specific Amino Acids Level
1860 - Chemoresistant Leukemia-Initiating Cell Expansion Is Inhibited By Targeting Oncogenic Self-Renewal
2377 - A Conserved Cis-Regulatory Retinoic Acid Responsive Element Is Essential for Maintenance of Primitive Hematopoietic Stem Cells through Regulation of Hoxb Cluster
1860 - Chemoresistant Leukemia-Initiating Cell Expansion Is Inhibited By Targeting Oncogenic Self-Renewal
2377 - A Conserved Cis-Regulatory Retinoic Acid Responsive Element Is Essential for Maintenance of Primitive Hematopoietic Stem Cells through Regulation of Hoxb Cluster
Qian, W.
Qian, Y.
Qian, Y.
675 - BRD4 Proteolysis Targeting Chimera (PROTAC) Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Leukemias and Overcomes Stroma Mediated Resistance By Modulating Surface Expression of CXCR4
917 - Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma
2050 - BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL
917 - Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma
2050 - BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL
Qian, Z.
Qiang, Y. W.
Qiao, C.
Qiao, J.
156 - HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group
Qiao, J.
156 - HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group
455 - Microtransplantation Improved Outcome in Elderly Acute Myeloid Leukemia Patients - Report from China Microtransplantation Cooperative Group
Qiao, N.
Qiao, W.
Qiao, Z.
Qin, H.
100 - CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells
1432 - CRLF2/Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells
2524 - Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR
4427 - Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
1432 - CRLF2/Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells
2524 - Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR
4427 - Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
Qin, M.
382 - Safety and Functional Studies of Ex Vivo Generated Megakaryocytic Progenitors/Platelets in a Myeloablative Non-Human Primate Model
1899 - Functional Studies of Ex Vivo Expanded Hematopoietic Stem Cells in Mice and Monkeys
4302 - Functional Evaluations of Ex Vivo Induced Endothelial Progenitors for Autologous Transplantation in Non-Human Primates
1899 - Functional Studies of Ex Vivo Expanded Hematopoietic Stem Cells in Mice and Monkeys
4302 - Functional Evaluations of Ex Vivo Induced Endothelial Progenitors for Autologous Transplantation in Non-Human Primates
Qin, T.
Qin, X.
Qin, X. Y.
Qin, X.
Qin, Y.
1970 - Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Might Overcome the Adverse Effect of Minimal Residue Disease Pretransplant in Patients with Standard-Risk Acute Myeloid Leukemia
2006 - CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor
2006 - CTLA-4 Polymorphisms and Haplotype Correlate with Survival and aGVHD after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor
Qin, Y.
Qin, Y.
Qin, Z.
Qing, C.
Qiu, H.
Qiu, J.
Qiu, L.
1725 - Intratumoral Genetic Heterogeneity Provides Additional Prognostic Significance of the CLL Genomic Features
3870 - Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults
3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders
4253 - Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide
3870 - Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults
3879 - Different Prognostic Significance of a Panel Cytogenetic Aberrations Between Chronic Lymphocytic Leukemia and Other B-Cell Chronic Lymphoproliferative Disorders
4253 - Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide
Qiu, L.
730 - Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial
4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial
4240 - Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial
Qiu, L.
839 - Drug Resistant Myeloma Cells Cause More Severe Bone Destruction in Myeloma
1513 - Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
1784 - Clonal Evolution Paths Significantly Impact the Outcome of Myeloma
1810 - APRIL/B Cell Maturation Antigen (BCMA) Signaling Cascades Promote Human Multiple Myeloma Growth and Mediate Immunosuppression in the Bone Marrow Microenvironment Via IL-10, TGF-b, and PD-L1
2448 - Pathological Roles of p18 Deficiency Toward B Cell Malignances
2480 - Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma
4186 - Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis
1513 - Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
1784 - Clonal Evolution Paths Significantly Impact the Outcome of Myeloma
1810 - APRIL/B Cell Maturation Antigen (BCMA) Signaling Cascades Promote Human Multiple Myeloma Growth and Mediate Immunosuppression in the Bone Marrow Microenvironment Via IL-10, TGF-b, and PD-L1
2448 - Pathological Roles of p18 Deficiency Toward B Cell Malignances
2480 - Suppression of Cdc37 Induces Bortezomib Resistance through Autophagy Activation and Plasma Cell Immaturation in Multiple Myeloma
4186 - Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis
Qiu, Q.
Qiu, Q.
Qiu, S.
Qiu, Y.
1198 - Role of Mesenchymal Stem Cell Galectin 3 in the AML Tumor Microenvironment
1398 - Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML
3680 - Focal Adhesion Kinase As a Potential Target in AML and MDS
3813 - Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC
1398 - Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML
3680 - Focal Adhesion Kinase As a Potential Target in AML and MDS
3813 - Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC
Qiu, Y.
Qiu, Y.
Qu, C.
Qu, P.
1777 - Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma
1806 - The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma
1808 - Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines
2982 - Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma
1806 - The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma
1808 - Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines
2982 - Deletion of TP53 (17p13) Is Associated with Poor Outcome for Newly Diagnosed High-Risk Multiple Myeloma
Qu, X.
Qu, X.
Quach, H.
344 - Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study
495 - Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
4206 - High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma
4236 - Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials
495 - Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)
4206 - High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma
4236 - Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials
Quadrelli, C.
Quaid, S.
Quarello, P.
Quarmyne, M. O.
Quarmyne, M. O.
Quarmyne, M.
Quarona, V.
Quartey, E.
Quast, T.
Quattrocchi, L.
Quayle, S. N.
Queau, M.
1742 - A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
4163 - An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
4163 - An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
Quehenberger, P.
652 - Thrombotic Events in Lupus Anticoagulant Positive Patients Prospectively Correlate with Clinical Risk Factors - the Vienna Lupus Anticoagulant and Thrombosis Study (LATS)
718 - Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia
718 - Ristocetin-Induced Platelet Aggregation for Monitoring of Bleeding Tendency in Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia
Quehenberger, P.
Queipo De Llano, M. P.
Queizan, J.
Queizán, J. A.
Quek, K.
Quentmeier, H.
Quéré, I.
Querfeld, C.
Querrey, M.
Quesenberry, P. J.
Quesnel, B.
Quettier, M.
Queudeville, M.
Queva, C.
2482 - Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line
3697 - Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors
3707 - Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib
3697 - Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors
3707 - Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib
Quéva, C.
1749 - Combination Effects of B Cell Receptor Pathway Inhibitors (Entospletinib, ONO/GS-4059, and Idelalisib) and a BCL-2 Inhibitor in Primary CLL Cells
2485 - An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL
2485 - An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL
Quezado, Z.
Quick, D. P.
Quigley, M. T.
Quill, T. A.
Quillet-Mary, A.
Quinn, C. T.
Quinn, E.
Quinquenel, A.
Quintanilla-Fend, L.
Quintarelli, C.
1570 - Bone Marrow (BM) Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib
1931 - Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial
3093 - Immune Reconstitution after Adoptive Infusion of BPX501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial
4299 - BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)
1931 - Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial
3093 - Immune Reconstitution after Adoptive Infusion of BPX501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial
4299 - BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)
Quintas-Cardama, A.
Quintás-Cardama, A.
Quirindongo-Crespo, M.
Quirini, F.
2725 - Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma
3937 - Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients
3937 - Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients
Quittet, P.
577 - Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study
3932 - PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007
3932 - PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007
Quivoron, C.
Quock, T. P.
Quon, D.
39 - Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study
761 - A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population
761 - A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population
Quon, D. V.
Quota, A.
Qureshi, M.